Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD

Report from ACC: Experts advise reading the fine print of the study - which failed to show an overall outcome benefit - as sub-group analysis shows highest-risk patients might benefit.